Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Müller

Showing results (401-410 of 651) with videos related to

Pageof 66
Sort By:
Blood Advances|March 23, 2022
Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AMLSebastian Stasik, Clara Burkhard-Meier, Michael Kramer, et al.
Cell Communication and Signaling : CCS|July 13, 2012
Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expressionDeepika Arora, Susanne Köthe, Monique van den Eijnden, et al.
Blood|January 13, 2011
Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like diseaseChristian Elling, Philipp Erben, Christoph Walz, et al.
Annals of the Rheumatic Diseases|April 1, 2024
Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic diseaseKarolina Gente, Manuel Feisst, Dorothea Marx, et al.
Cold Spring Harbor Molecular Case Studies|July 7, 2017
Metastatic triple-negative breast cancer patient with <i>TP53</i> tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse eventsTobias Meißner, Adam Mark, Casey Williams, et al.
Molecular Cancer Therapeutics|December 10, 2020
HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma CellsVianihuini Figueroa-Vazquez, Jonathan Ko, Christian Breunig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targetsCarsten Müller-Tidow, Joachim Schwäble, Björn Steffen, et al.
Journal of Cachexia, Sarcopenia and Muscle|December 13, 2021
Validation of a proxy-reported SARC-F questionnaire for current and retrospective screening of sarcopenia-related functional impairmentsJohannes Maurus, Tobias Terzer, Axel Benner, et al.
Transfusion|April 11, 2026
Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment responseHanna Kuhn, Felix Korell, Angela Hückelhoven-Krauss, et al.
International Journal of Cancer|July 20, 2020
Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patientsFuli Fan, Hyeon Joo Yoo, Sophia Stock, et al.
Pageof 66

Showing results (401-410 of 651) with videos related to

Sort By:
Pageof 66
Blood Advances|March 23, 2022
Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AMLSebastian Stasik, Clara Burkhard-Meier, Michael Kramer, et al.
Cell Communication and Signaling : CCS|July 13, 2012
Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expressionDeepika Arora, Susanne Köthe, Monique van den Eijnden, et al.
Blood|January 13, 2011
Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like diseaseChristian Elling, Philipp Erben, Christoph Walz, et al.
Annals of the Rheumatic Diseases|April 1, 2024
Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic diseaseKarolina Gente, Manuel Feisst, Dorothea Marx, et al.
Cold Spring Harbor Molecular Case Studies|July 7, 2017
Metastatic triple-negative breast cancer patient with <i>TP53</i> tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse eventsTobias Meißner, Adam Mark, Casey Williams, et al.
Molecular Cancer Therapeutics|December 10, 2020
HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma CellsVianihuini Figueroa-Vazquez, Jonathan Ko, Christian Breunig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targetsCarsten Müller-Tidow, Joachim Schwäble, Björn Steffen, et al.
Journal of Cachexia, Sarcopenia and Muscle|December 13, 2021
Validation of a proxy-reported SARC-F questionnaire for current and retrospective screening of sarcopenia-related functional impairmentsJohannes Maurus, Tobias Terzer, Axel Benner, et al.
Transfusion|April 11, 2026
Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment responseHanna Kuhn, Felix Korell, Angela Hückelhoven-Krauss, et al.
International Journal of Cancer|July 20, 2020
Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patientsFuli Fan, Hyeon Joo Yoo, Sophia Stock, et al.
Pageof 66